Atrial fibrillation (AF) is the most common arrhythmia, and despite progress with catheter ablation and pulmonary vein isolation, there is a need for pharmacological treatment alternatives. Few new pharmacological options have been added during the last decade and there is a need for improved risk markers to avoid pro-arrhythmias (Lafuente-Lafuente et al., 2012).